PMID- 37056451 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2325-9671 (Print) IS - 2325-9671 (Electronic) IS - 2325-9671 (Linking) VI - 11 IP - 4 DP - 2023 Apr TI - Survivorship, Outcomes, and Risk Factors for Conversion to Total Hip Arthroplasty After Revision Hip Arthroscopic Surgery in Obese Patients: Results at a Minimum 5-Year Follow-up. PG - 23259671231154921 LID - 10.1177/23259671231154921 [doi] LID - 23259671231154921 AB - BACKGROUND: There is a paucity of literature reporting outcomes after revision hip arthroscopic surgery in obese patients. PURPOSE: To report the minimum 5-year survivorship, patient-reported outcomes (PROs), clinical benefit, and risk factors for conversion to total hip arthroplasty (THA) in obese patients after revision hip arthroscopic surgery. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Data were prospectively collected and retrospectively reviewed for patients who underwent revision hip arthroscopic surgery by a single surgeon between April 2010 and August 2016. Inclusion criteria were a body mass index >/=30 and baseline and minimum 5-year postoperative values for the modified Harris Hip Score (mHHS), Nonarthritic Hip Score (NAHS), Hip Outcome Score-Sport-Specific Subscale (HOS-SSS), and visual analog scale (VAS) for pain. Exclusion criteria were Tonnis grade >1 and hip dysplasia. Survivorship was defined as no conversion to THA. Clinical benefit was measured using the minimal clinically important difference (MCID). Survivors and nonsurvivors underwent further bivariate and regression analyses to determine the predictors of conversion to THA. RESULTS: Included were 24 hips in 24 patients. The mean patient age was 39.3 +/- 12.7 years, and the mean follow-up was 83.9 +/- 26.5 months. The survivorship rate was 75.0%, and patients demonstrated a significant improvement in all PROs (P < .01). At 5-year follow-up, the MCID for the mHHS, NAHS, HOS-SSS, and VAS was achieved by 70.6%, 94.1%, 92.9%, and 64.7%, respectively, of the patients. Older age, higher grade ligamentum teres tears, and acetabuloplasty were significant on bivariate analysis for conversion to THA, and increased age was identified as a significant variable for conversion to THA on regression analysis (odds ratio, 1.297 [95% CI, 1.045-1.609]; P = .018), with a 29.7% greater risk for every additional year of age at the time of revision. CONCLUSION: In this study, 25.0% of obese patients who underwent revision hip arthroscopic surgery required conversion to THA. The study patients who did not need conversion to THA had a significant improvement in all PROs, with >90% achieving MCID for one or more outcome measures. Older age was identified as a significant predictor of conversion to THA. CI - (c) The Author(s) 2023. FAU - Maldonado, David R AU - Maldonado DR AD - Department of Orthopaedic Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA. FAU - Lee, Michael S AU - Lee MS AD - American Hip Institute Research Foundation, Chicago, Illinois, USA. FAU - Kyin, Cynthia AU - Kyin C AD - American Hip Institute Research Foundation, Chicago, Illinois, USA. FAU - Jimenez, Andrew E AU - Jimenez AE AD - American Hip Institute Research Foundation, Chicago, Illinois, USA. FAU - Owens, Jade S AU - Owens JS AD - American Hip Institute Research Foundation, Chicago, Illinois, USA. FAU - Perez-Padilla, Paulo A AU - Perez-Padilla PA AD - American Hip Institute Research Foundation, Chicago, Illinois, USA. FAU - Domb, Benjamin G AU - Domb BG AD - American Hip Institute Research Foundation, Chicago, Illinois, USA. AD - American Hip Institute, Chicago, Illinois, USA. LA - eng PT - Journal Article DEP - 20230406 PL - United States TA - Orthop J Sports Med JT - Orthopaedic journal of sports medicine JID - 101620522 PMC - PMC10087662 OTO - NOTNLM OT - body mass index OT - hip arthroscopic surgery OT - outcomes OT - revision OT - survivorship COIS- One or more of the authors has declared the following potential conflict of interest or source of funding: D.R.M. has received research support from Arthrex; education payments from Arthrex, Micromed, and Smith & Nephew; speaking fees from Arthrex; and hospitality payments from Stryker. A.E.J. has received grant support and education payments from Arthrex. B.G.D. has received research support from Arthrex, ATI, the Kauffman Foundation, Pacira Pharmaceuticals, and Stryker; has received consulting fees from Adventist Hinsdale Hospital, Arthrex, MAKO Surgical, Medacta, Pacira Pharmaceuticals, and Stryker; has received educational support from Arthrex and Breg; has received speaking fees from Arthrex, Pacira Pharmaceuticals, and Stryker; has received honoraria from Medacta; has received royalties from Amplitude, Arthrex, DJO, MAKO Surgical, Medacta, Orthomerica, and Stryker; and has had ownership interests in the American Hip Institute, SCD#3, Hinsdale Orthopaedics, the Munster Specialty Surgery Center, and North Shore Surgical Suites. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. EDAT- 2023/04/15 06:00 MHDA- 2023/04/15 06:01 PMCR- 2023/04/06 CRDT- 2023/04/14 02:27 PHST- 2022/10/13 00:00 [received] PHST- 2022/11/08 00:00 [accepted] PHST- 2023/04/15 06:01 [medline] PHST- 2023/04/14 02:27 [entrez] PHST- 2023/04/15 06:00 [pubmed] PHST- 2023/04/06 00:00 [pmc-release] AID - 10.1177_23259671231154921 [pii] AID - 10.1177/23259671231154921 [doi] PST - epublish SO - Orthop J Sports Med. 2023 Apr 6;11(4):23259671231154921. doi: 10.1177/23259671231154921. eCollection 2023 Apr.